Drug shows promise in overcoming endocrine therapy resistance in breast cancer

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

BET inhibitors, a class of drugs already in clinical trials, might work especially well in breast cancer patients who have acquired a Y537S mutation, according to a preclinical study led by researchers at UT Southwestern Medical Center.

To access this subscriber-only content please log in or renew your subscription.

Looking for IP Login? Our IP Login system is now automatic. If your institution has a site license, please log in from on site or via your VPN to access this content.

Login Subscribe
Table of Contents

YOU MAY BE INTERESTED IN

Login